Abstract This study aimed to characterize the β-adrenoceptor (β-AR) subtype mediating relaxation of isolated human bladder strips and to explore relaxation by the novel β3-AR-selective agonist KUC-7322 for its relaxant effect on the human isolated detrusor and for its effect on the carbachol (CCh)-induced contractile response. In two parallel studies, relaxation of isolated human bladder strips was tested for the β-AR agonists isoproterenol, clenbuterol, BRL 37344, and KUC-7322. For the isoproterenol and KUC-7322 responses, antagonism by CGP 20712A, ICI 118551, and SR59230A was determined. The potency and efficacy of the reference agonists for detrusor relaxation was in line with their known β3-AR activity. KUC-7322 relative to isoproterenol was a full agonist with a pEC 50 of 5.95± 0.09 and 5.92±0.11 in the two studies. SR59230A exhibited antagonism of the expected potency against isoproterenol (apparent pK B 7.2) but not against KUC-7322. Neither isoproterenol nor KUC-7322 nor forskolin significantly attenuated CCh-induced contraction. These results suggest that KUC-7322 displays full agonistic activity in relaxing the human detrusor without inhibiting the contraction induced by cholinergic stimulation. These characteristics, if proven in vivo, may be beneficial for the treatment of overactive bladder, as increased bladder capacity with a negligible effect on voiding contractions may be anticipated.
Introduction
The sympathetic nervous system contributes to urine storage by relaxing the detrusor via activation of β-adrenoceptors (β-ARs) (Nergardh et al. 1978; Norlen et al. 1978) . In the human bladder, more than 97 % of the total β-AR mRNA belongs to the β3-AR subtype (Nomiya and Yamaguchi 2003) . Accordingly, several studies based on the potency and efficacy of several subtype-selective agonists have indicated that relaxation of human detrusor smooth muscle occurs primarily via β3-AR (Badawi et al. 2005 (Badawi et al. , 2007 Biers et al. 2006; Igawa et al. 1998 Igawa et al. , 1999 Igawa et al. , 2001 Li et al. 2003; Morita et al. 2000; Nomiya and Yamaguchi 2003; Otsuka et al. 2008a; Takasu et al. 2007; Takeda et al. 1999; Yamanishi et al. 2006) . Confirmation of these findings by subtype-selective antagonists has been obtained in fewer studies (Igawa et al. 1999; Otsuka et al. 2008a; ) and the evidence has remained equivocal (Biers et al. 2006; Frazier et al. 2011) . Nevertheless, β3-ARs have become an attractive target for novel drugs for the treatment of patients suffering from the overactive bladder syndrome. This proposal is supported by consistent findings from many animal models of bladder dysfunction in which β-AR agonists were effective (Michel et al. 2011b) . Moreover, the β3-AR-mediated relaxation is preserved even in detrusors taken from patients with neurogenic detrusor overactivity or a low compliance bladder (Igawa et al. 2001) .
Accordingly, β3-AR agonists such as solabegron (also known as GW427353, Biers et al. 2006; Hicks et al. 2007) or mirabegron (also known as YM178, Takasu et al. 2007) have been introduced and are currently undergoing clinical evaluation. Ritobegron (also known as KUC-7483) is a novel compound developed in the search for a promising drug for overactive bladder syndromes carried out by Kissei Pharmaceutical Co. Ltd. After oral administration, KUC-7483 is rapidly converted to KUC-7322, a selective β3-AR agonist (Maruyama et al. 2012) . It was recently reported (a) that KUC-7322 has selective agonistic activity for the human β3-AR and a potent relaxing effect on the isolated rat bladder via stimulation of β3-AR and (b) that it decreases intravesical pressure in rats with minimal effects on the cardiovascular system (Maruyama et al. 2012) . In the present study, we characterized the β-AR subtype mediating human detrusor relaxation based on agonists and antagonists and determined the ability of KUC-7322 to cause relaxation and to prevent contraction of isolated human detrusor.
Methods

Patients and specimens
Study I involved 15 patients (11 men and four women; aged 68.1± 3.2 years) from Shinshu University Hospital, and study II involved eight patients (six men and two women; aged 61.8±4.6 years) from the Universitätsklinikum Essen. Both studies were in line with the Declaration of Helsinki and had been approved by the respective ethical committees; all patients had provided written informed consent.
All patients had neurologically normal bladder function and underwent open pelvic surgery for bladder carcinoma. On the basis of the preoperative clinical and neurological examinations, none of the patients had apparent lower urinary tract dysfunction. No patient had diseases known to interfere with the β-AR system or was receiving medication known to interfere with that system. General anesthesia was induced with a short-acting barbiturate and then maintained with fentanyl and a mixture of oxygen, nitrous oxide, and isoflurane. All specimens were taken from macroscopically normal tissue in the anterior or posterior wall of the bladder body. The specimens were placed in ice-cold buffer immediately after excision and transported to the laboratory.
Functional studies
The detailed experimental protocols used in studies I and II have been reported by Igawa et al. (1999) and , respectively. Briefly, in study I, detrusor muscle strips of approximately 10×5×3 mm were isolated after the mucosa and adventitia had been removed, whereas detrusor muscle strips of approximately 15×1×1 mm were isolated in study II, where the mucosa and adventitia had not routinely been removed. Each preparation was suspended in a 10-ml organ bath containing Krebs solution of the following composition (mM): NaCl 119, KCl 4.7, MgSO 4 1.2, Na 4 EDTA 0.027, CaCl 2 2.5, KH 2 PO 4 1.2, NaHCO 3 25, supplemented with 11 mM glucose (study I) or 5.5 mM glucose and 10 mM HEPES (study II); this was maintained at 37°C and continuously gassed with a mixture of 95 % O 2 and 5 % CO 2 to maintain a pH of 7.4. One end of each strip was connected to a force-displacement transducer, and changes in muscle tension were measured and recorded on a pen-writing oscillograph or chart recorder. The preparation was gradually stretched until a stable tension of 10 mN was obtained.
Agonist concentration-response curves were generated for a given drug by cumulative addition to the bathing fluid. For relaxation experiments, this was done against a resting tension of 10 mN (study I) or 20 min after contraction had been induced by addition of 50 mM KCl, at which time a stable tone 34±2 mN had been obtained (study II). At the end of each relaxation experiment, 10 μM forskolin was added to determine receptor-independent relaxation. For contraction studies (study I), a carbachol (CCh) concentration-response curve was generated, the bladder strips were washed and then exposed to the indicated concentration of β-AR agonist or muscarinic antagonist, and 30 min later, a second CCh concentration-response curve was generated. All experiments of study I were performed in the presence of 1 μM of the α-AR antagonist phentolamine. Other than for CCh, only one agonist concentration-response curve was obtained from each preparation. We have documented the reproducibility of two consecutive CCh concentrationresponse curves in human detrusor strips previously (Schneider et al. 2004 ).
Data analysis
Results are presented as the mean plus or minus the standard error of mean (SEM). The relaxant effect of a given drug was expressed as a percentage of the maximal relaxation induced by 10 μM forskolin, which was used as a reference drug. EC 50 values were calculated by non-linear iterative regression analysis. This was done for each individual experiment, and the quantitative data being shown represent the means ± SEM of n experiments. The curves being shown in the figures, however, are for illustration only being represented by the fit for the pooled data of all experiments. For the inhibitory effect of a given drug on the CCh-induced contraction, the maximum response in the concentrationresponse curve obtained for CCh before drug treatment was defined as 100 %. When a test drug caused a rightward shift of the CCh-induced concentration-response curve, an apparent pK B value was calculated using the following formula: pK B 0log (CR−1)−log [antagonist] , where CR is the ratio of CCh concentrations that induced a similar response (i.e., half-maximal response) between the presence and absence of the test drug. All curve fitting procedures were done using the Prism program (Graphpad Software, San Diego, CA, USA).
Drugs and solutions
The following drugs were used: (±)-isoproterenol HCl, flavoxate HCl, forskolin (Wako Pure Chemical, Osaka, Japan), BRL 37344 sodium salt hydrate (BRL 37344,
tolterodine tartrate, and propiverine hydrochloride were synthesized by Kissei Pharmaceutical Co. Ltd. (Matsumoto, Japan). Forskolin was dissolved in 100 % DMSO, all other drugs in distilled water. The solutions were prepared on the day of the experiment and kept in dark vessels to minimize light-induced degradation. The subsequent dilutions of the drugs are expressed as the calculated final concentration in the bath solutions.
Results
Study I: relaxant effect of each drug Forskolin (10 μM) reduced human detrusor tension to 42± 3 % (n040) of the initial tension. Isoproterenol (0.1 nM-100 μM), a non-subtype-selective β-AR agonist, induced relaxation in a concentration-dependent manner (Figs. 1a and 2a, Table 1 ). Its maximal effect, obtained at 100 μM, was 87±4 % of the forskolin-induced relaxation. Clenbuterol (0.1 nM-100 μM), a β 2 -AR agonist, induced a smaller and more variable relaxation (52±15 %; Figs. 1b and 2a, Table 1 ). BRL 37344 (0.1 nM-100 μM), a classic β3-AR agonist, had a calculated E max of 61±10 % (Figs. 1c and 2a, Table 1 ). On the other hand, the novel β3-AR agonist KUC-7322 (0.1 nM-100 μM) relaxed the human detrusor in a concentration-dependent manner (Figs. 1d and 2a, Table 1 ) with the maximal effect at 100 μM being 87±2 % of the forskolin-induced relaxation; thus, its maximal effect was comparable to that of isoproterenol. The pEC 50 values for the relaxant effects of isoproterenol and KUC-7322 were 6.66±0.19 and 5.95±0.09, respectively (Table 1) . Table 1 Tolterodine (0.1 nM-100 μM), an anti-muscarinic drug, induced only a slight relaxation even at 100 μM (20±4 %; Fig. 2b ). The muscarinic antagonists oxybutynin and propiverine did not induce any significant relaxation even at 100 μM, nor did flavoxate, an anti-spasmodic drug (Fig. 2b) . Moreover, high concentrations (10-100 μM) of the latter three drugs induced contraction of detrusor preparations.
Study II: antagonist experiments
When testing against KCl-induced tone, 10 μM forskolininduced relaxation was 69±3 %. Under these conditions, isoproterenol and KUC-7322 also caused concentrationdependent detrusor smooth muscle relaxation with maximum effects of 75 ± 3 and 65 ± 5 %, respectively; the corresponding pEC 50 values were 6.93±0. 19 and 5.92± 0.11, respectively (n014 and 13, respectively) .
As compared to strips tested in the absence of antagonist, the β1-AR antagonist CGP 20712A (1-10 μM, n05-11), the β2-AR antagonist ICI 118551 (1 and 10 μM, n06-8) and the general β-AR antagonist SR59230A (1-10 μM, n0 14 each) did not significantly affect forskolin-induced relaxation in a repeated-measures ANOVA (data not shown), although in line with previous observations in rat bladder (Frazier et al. 2011) , SR59230A numerically reduced starting tension prior to β-AR agonist administration by 44-60 %. None of the antagonists significantly affected forskolin-induced detrusor relaxation (data not shown).
CGP 20712A at a concentration of 1 μM, i.e., 352-, 0.56-, and 0.18-fold its affinity at human β1-, β2-, and β3-AR, respectively (Hoffmann et al. 2004; Baker 2005; Niclauß et al. 2006) , caused a parallel right shift of the isoproterenol concentration-response curve by about 50-fold (Fig. 3) , indicating an apparent pK B value of about 7.7. CGP 20712A (1 μM) caused a smaller and non-parallel right shift of the KUC-7322 concentration-response curve by about 30-fold (Fig. 3) , indicating an apparent pK B value of about 7.5. Experiments with 3 and 10 μM CGP 20712A did not yield appreciable additional right shifts for either agonist (data not shown).
ICI 118551 at concentration of 1 μM, i.e., 3-, 645-, and 0.81-fold its affinity at human β1-, β2-, and β3-AR, respectively (Hoffmann et al. 2004; Baker 2005; Niclauß et al. 2006) , caused only minor if any right shifts of the isoproterenol or the KUC-7322 concentration-response curve (Fig. 4) , and even at a concentration of 10 μM, no clear right shift was detected (data not shown), indicating a lack of β2-AR involvement in the response to both agonists in human detrusor.
SR59230A at a concentration of 1 μM, i.e., 29-, 74-, and 12-fold its affinity at human β1-, β2-, and β3-AR, respectively (Hoffmann et al. 2004; Niclauß et al. 2006; Baker 2010) , caused a right shift of the isoproterenol concentration-response curve by about 20-fold (Fig. 5) , indicating an apparent pK B value of about 7.2. Higher concentrations did not cause concentration-related additional right shifts. In contrast, neither 1 nor 3 μM caused relevant inhibition of the relaxation response to KUC-7322 (Fig. 5) , and even at 10 μM, no relevant shift was observed (data not shown).
Study I: inhibitory effect of each drug against CCh-induced contraction CCh (30 nM-100 μM) induced a concentration-dependent contraction of the human detrusor. The maximum contraction induced by CCh was 71±5 mN at 30 μM, and the EC 50 value was estimated to be 1.8±0.31 μM. Atropine (100 nM), tolterodine (1 μM), oxybutynin (1 μM), and propiverine (10 μM) all caused rightward shifts of the concentration-response curve for CCh (Fig. 6 ). The pK B values calculated for atropine, tolterodine, oxybutynin, and propiverine were 8.79±0.14, 7.83±0.14, 7.76±0.32, and 5.52 ± 0.16, respectively. The presence of forskolin (10 μM), isoproterenol (10 nM-100 μM), or KUC-7322 (10 nM-100 μM) had only limited effect on CCh-induced contractions CCh (Fig. 6 ).
Discussion
Critique of methods
The present manuscript reports findings from two separate studies performed in two laboratories in two different countries. The two patient populations that have been used differed slightly in age, but previous work has shown that such minor age differences have only small if any effects on isoproterenol-induced relaxation of human detrusor strips (Li et al. 2003; Schneider et al. 2011) . Studies I and II have been performed in different ethnic groups, i.e., in samples from Japanese and German patients, respectively. While this raises the possibility of ethnic differences, we are not aware of any study in the literature ever describing racial differences in bladder responses to KUC-7322 or to betaadrenergic agonists in general. However, it has been reported that the human β3-AR gene is polymorphic and that the prevalence of the most common polymorphism Trp64Arg differs between ethnicities (Belfer et al. 2005; Honda et al. 2006; Walton et al. 1995) . The relevance of this differential genotype preference, however, is uncertain as it has not been consistently associated with altered agonist responses (Vrydag et al. 2009 ). Our current findings that the potency of both isoproterenol and KUC-7322 is virtually identical in studies I (Japanese patients) and II (German patients) further support that there is no major ethnic difference for β-adrenergic bladder relaxation. The two studies also involved minor differences in protocol, the most important of which is that study I tested relaxation against basal (passive) tension, whereas study II measured relaxation against KCl-induced tone. Previous studies in rat (Frazier et al. 2005; Michel and Sand 2009 ) and human detrusor strips ) had demonstrated that isoproterenol had a similar potency to induce relaxation against passive tension and KCl-induced tone, although minor numerical differences yielded statistical significance in some cases. While a statistical analysis of observed numerical differences in agonist potency between studies I and II is not meaningful, the potency of both agonists was comparable against passive tension and KCl-induced tone in the present study as well. β-AR agonists may affect bladder function not only at the smooth muscle cell level but also indirectly via the urothelium (Birder et al. 2002) . However, it has remained controversial whether urothelium removal affects the relaxation response to β-AR agonists in isolated detrusor strips (Kullmann et al. 2011; Murakami et al. 2007; Otsuka et al. 2008b; Propping et al. 2009 ). Interestingly, the potency of isoproterenol and KUC-7322 was similar in both of our studies despite urothelium removal in study I but not in study II.
The present studies are based on the potency of various β-AR agonists and antagonists. Isoproterenol is a reference agonist exhibiting similar potency for all three β-AR subtypes and has slightly lower affinity for the β3-AR as compared to the other two subtypes (Baker 2010; Hoffmann et al. 2004) . Clenbuterol is about 20-and 300-fold selective for β2-AR as compared to β1-AR and β3-AR (Baker 2010) . BRL 37344 was reported to be 90-and 20-fold selective for human β3-AR over β1-AR and β2-AR, respectively, in one study (Hoffmann et al. 2004 ), but another study did not find any selectivity over β2-AR and only 20-fold selectivity over β1-AR (Baker 2010); moreover, BRL 37344 is only a partial agonist at human β3-AR (Baker 2010; Hoffmann et al. 2004) . This may at least partly explain why BRL 37344 exhibited a smaller maximum relaxation as compared to isoproterenol in the present study and in previous rat studies (Fazier et al. 2006) . CGP 20712A is a β1-AR antagonist with >500-fold selectivity over β2-AR and β3-AR (Baker 2005; Hoffmann et al. 2004; Niclauß et al. 2006) , whereas ICI 118551 is a β2-AR antagonist with a >50-and >800-fold selectivity over β1-AR and β3-AR (Baker 2005; Hoffmann et al. 2004; Niclauß et al. 2006) . SR59230A is widely used as a β3-AR antagonist, but contrary to common belief lacks relevant selectivity for the human β3-AR (Baker 2010; Hoffmann et al. 2004; Niclauß et al. 2006) . Moreover, SR59230A displays ligand-directed signaling/biased agonism at β3-AR ) and can be a partial agonist for some β3-AR-mediated responses including relaxation of rat bladder smooth muscle (Frazier et al. 2011) . These selectivity profiles need to be taken into consideration in the interpretation of our functional data.
The apparent affinity of an antagonist in functional assays is preferentially explored by Schild analysis based on multiple antagonist concentrations. However, because of potential desensitization and preparation run-down issues with human detrusor strips, we have performed only one agonist concentration-response curve per muscle strip, and the number of human samples did not allow the parallel testing of multiple antagonist concentrations.
Detrusor relaxation findings
Several previous studies have characterized β-AR subtypes mediating human detrusor strip relaxation in vitro; most of these studies were based on subtype-selective agonists and only a minority has also employed subtype-selective antagonists. Based on the potency and efficacy of the reference agonists isoproterenol, noradrenaline, and adrenaline; the β1-agonist dobutamine; the β2-agonists clenbuterol, procaterol, salbutamol, and terbutaline; and the β3-agonists 138- 355, AJ-9677, BRL 37344, CL-316243, GS 332, L 755,507, mirabegron, solabegron, and ZD 7114 , it has generally been claimed that human detrusor smooth muscle relaxation is a β3-AR-mediated response (Badawi et al. 2005 (Badawi et al. , 2007 Biers et al. 2006; Igawa et al. 1998 Igawa et al. , 1999 Igawa et al. , 2001 Li et al. 2003; Morita et al. 2000; Nomiya and Yamaguchi 2003; Otsuka et al. 2008a; Takasu et al. 2007; Takeda et al. 1999; Yamanishi et al. 2006) . The potency and efficacy of isoproterenol, clenbuterol, and BRL 37344 in the present study is in line with those previous reports and validates our preparation.
The reported antagonist studies were largely in line with the conclusions from the agonist studies but did not yield unequivocal findings. Thus, isoproterenol responses were inhibited by SR58894 but only poorly by CGP 20712A or ICI 118551 (Igawa et al. 1999) or inhibited by SR59230A but only poorly by atenolol or butoxamine . Antagonism of isoproterenol responses by SR59230A has also been reported by others in isolated human bladder strips (Otsuka et al. 2008a; Frazier et al. 2011) and was reproduced in our present study. On the other hand, SR59230A yielded only limited inhibition of the human detrusor relaxation response to solabegron (Biers et al. 2006) or nebivolol (Frazier et al. 2011) .
The primary novelty of the present study lies in the description of the effects of the novel β3-AR agonist KUC-7322 on human detrusor smooth muscle tone. KUC-7322 is the active metabolite of ritobegron (also known as KUC-7483) and was reported to be 301-and 32-fold selective for β3-AR over β1-AR and β2-AR for stimulation of cAMP formation by cloned human receptor subtypes; a similar selectivity profile was obtained by comparing its potency for relaxation of rat bladder as compared to rat atrium and myometrium (Maruyama et al. 2012) . In two series of experiments performed with similar protocols but with bladder strips from Japanese and German patients, we have demonstrated that KUC-7322 is 0.7-1.0 log units less potent than the reference agonist isoproterenol but has a comparable efficacy. These findings are in line with findings for rat detrusor relaxation, where KUC-7322 also was slightly less potent but similarly efficacious as isoproterenol (Maruyama et al. 2012) . In rats, these in vitro findings translated into a dosedependent reduction of intravesicular pressure in anesthetized animals in vivo by ritobegron, the prodrug of KUC-7322 (Maruyama et al. 2012) . These findings suggest that in contrast to several other agonists (Michel et al. 2011a ), ritobegron and KUC-7322 have similar potency and efficacy at rat and human β3-AR, which facilitates extrapolation from rodent findings to the human situation. Taking the similarity of the in vitro findings in rat and human detrusor strips and the in vivo data in rats into account, ritobegron appears to have promise for the treatment of human OAB.
As expected, neither the anti-muscarinic drugs tolterodine, oxybutynin, and propiverine nor the antispasmodic drug flavoxate affected the basal tone of the human detrusor in the present study, as all of them act preferentially against contractions induced by the endogenous parasympathetic transmitter acetylcholine or exogenous muscarinic agonists. Propiverine, in contrast to the other muscarinic receptor antagonists, has direct inhibitory effects on L-type Ca 2+ channels (Wuest et al. 2005) . This may explain why propiverine exhibited minor reductions of detrusor tone in the Fig. 6 Effects of a atropine (100 nM), tolterodine (1 μM), oxybutynin (1 μM), and propiverine (10 μM); b isoproterenol (Iso, 10 nM-100 μM) and forskolin (10 μM); and c KUC-7322 (KUC, 10 nM-100 μM) on the CCh-induced concentration-response curve in human detrusor preparations. Each data point represents the mean ± SEM from five to seven experiments. Data are expressed as a percentage of the maximum response in the CCh concentration-response curve obtained before treatment with a given drug present study. On the other hand, the findings that these were only minor despite the important role of L-type Ca 2+ channels for detrusor contraction (Frazier et al. 2008) indicate that this ancillary property of propiverine is unlikely to be of major clinical relevance. In contrast to the anti-muscarinics, β-AR agonists cause detrusor relaxation irrespective of the contractile stimulus (Michel and Sand 2009) , and this may lead to therapeutic advantages as the relative role of non-cholinergic stimuli for detrusor contractions increases under pathological conditions (Rapp et al. 2005) .
Some studies in isolated rat detrusor have indicated that bladder contraction by a muscarinic receptor agonist can be impaired in the presence of a β-AR agonist (Liang and Lo 2011) , whereas other studies in rabbits reported the opposite (Klausner et al. 2009 ). We therefore studied the effects of KUC-7322 and isoproterenol on the contractile response to CCh. Anti-muscarinic drugs (atropine, tolterodine, oxybutynin, and propiverine) caused the expected rightward shifts of the concentration-response curve for CCh-induced contraction of the human detrusor, thereby validating our experimental approach. However, neither isoproterenol nor KUC-7322 nor the receptor-independent adenylyl cyclase activator forskolin significantly attenuated CCh-induced contraction of human detrusor smooth muscle, indicating that neither the rat nor the rabbit detrusor may be predictive for the human situation in this regard.
In conclusion, our data confirm that β3-ARs are the most important β-AR subtype for causing human detrusor smooth muscle relaxation. They introduce KUC-7322, the active metabolite of ritobegron as a potent relaxant for the human bladder, and support the notion that selective β3-AR agonists as a class have potential for the treatment of patients suffering from the overactive bladder syndrome.
